Best of ASCO - 2014 Annual Meeting

 

Welcome

Antibodies

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.

Yoshitaka Ogita

TPS2599

A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.

David Michael Hyman

TPS2602

A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.

Sadhna Shankar

TPS2601

A phase I dose escalation study of hPV19, a novel humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in patients with advanced solid tumors refractory to standard therapy.

Dongmei Ji

2522

A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of TAB008 and bevacizumab in healthy volunteers.

Jacqueline M Liu

e14504

AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).

Lakshmi Rajdev

TPS2597

Can VEGFA and ICAM1 polymorphisms predict response to bevacizumab?

Apostolos Papachristos

2521

Evaluation of fixed-dose regimens of seribantumab in patients with solid tumors.

Bambang Adiwijaya

2524

First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.

Jeeyun Lee

e14501

MASTER KEY project: A basket/umbrella trial for rare cancers in Japan.

Hitomi Sumiyoshi Okuma

TPS2598

MSLN-targeting bispecific t-cell engaging antibody, MG1122, for treatment of solid tumors.

Yongyea Park

e14500

Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas.

Balaji Agoram

2525

PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.

Christophe Le Tourneau

2523

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.

Funda Meric-Bernstam

2500

The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.

Sebastian Ochsenreither

TPS2596

Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.

Geoffrey Shapiro

TPS2600